Early detection through PSA testing and digital rectal exams can identify prostate cancer before symptoms appear to improve patient outcomes [4, 5, 6].
Timely screening is vital because it allows for earlier treatment, which reduces mortality and increases survival rates [1, 4, 5]. Because the disease often develops without early symptoms, medical professionals said that proactive screening is the most effective way to catch the cancer in a treatable stage.
Prostate cancer is the most common cancer among American men [3]. Data indicates that approximately one in eight men will be diagnosed with the disease during their lifetime [1].
While the disease affects men generally, certain demographics face higher risks. Older men and Black men are particularly susceptible to the disease [1, 2, 3]. Medical experts said that early detection is essential for these high-risk groups to mitigate the impact of the illness [2].
Public health initiatives often peak during Prostate Cancer Awareness Month, observed each September [2, 3]. These campaigns aim to dispel myths and encourage men to seek screenings regardless of whether they feel ill [3, 6].
Screening typically involves the Prostate-Specific Antigen (PSA) test, a blood test that measures the level of a protein produced by the prostate [5]. When combined with a digital rectal exam, these tools provide a comprehensive view of prostate health. This dual approach helps clinicians identify abnormalities that may not be evident through physical symptoms alone [4, 6].
“Prostate cancer is the most common cancer among American men.”
The emphasis on early detection highlights a shift toward preventative screening in the U.S. healthcare system. By targeting high-risk populations, specifically Black men and older adults, health providers aim to close the gap in survival outcomes through standardized PSA and digital rectal exams.
